Research
Hormonal
Dual incretin agonists (GLP-1/GIP) such as tirzepatide demonstrate superior weight loss efficacy compared to single GLP-1 agonists.
Tirzepatide (15mg weekly) is a dual-acting drug (GLP-1/GIP) that produces greater weight loss (~21%) than single-acting GLP-1 drugs. It is currently approved for type 2 diabetes and under review for obesity. It requires weekly injection and medical supervision.
StrongSupportsHIGH confidence
Tirzepatide... was efficacious in ameliorating glycaemic control... and body weight... significant weight loss even reaching 20.9% mean change in body weight... with the 15 mg dose of tirzepatide
Why this rating
Based on multiple systematic reviews and large RCTs cited.
Source
Newer pharmacological interventions directed at gut hormones for obesity
Michael Camilleri et al. · British Journal of Pharmacology · 2023
narrative_reviewCited 24×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →